Quantum BioPharma Posts $17.3M Nine-Month Loss; Cash Rises to $3.56M on ATM and Debenture Funding
QNTM is trading near its 52-week low of $1.71 (4.1% above the low).
Summary
Quantum BioPharma's Q3 filing shows cash up to $3.56M and working capital of $5.47M, funded by $10.6M of ATM sales and C$3.75M of debentures, against a $17.3M nine-month net loss that is largely non-cash derivative remeasurement.
Key Events · Earnings and Guidance · QNTM
-
Nine-Month Loss Narrows to $17.3M
Net loss for the nine months ended September 30, 2026 was $17,320,779 versus $23,253,808 a year earlier; Q3 alone lost $474,279 versus $4,747,600.
-
Cash Rises to $3.56M, Working Capital $5.47M
Cash and equivalents were $3,556,345 at September 30, 2026, up from $1,905,357 at December 31, 2025; management cites working capital of $5,468,176 (December 31, 2025: $420,059).
-
ATM and Debentures Fund the Quarter
The company sold 2,815,674 Class B shares under its Rodman & Renshaw ATM for gross proceeds of $10,646,808, and issued C$3,750,000 of March 2026 debentures of which C$3,155,000 principal plus C$103,362 interest converted into 1,086,108 shares.
-
Derivative Remeasurement Drives Paper Loss
A $9,045,340 loss on fair value of derivative and warrant liabilities is non-cash; $2,167,602 of warrant liability and $684,619 of derivative liabilities sat on the balance sheet at September 30, 2026.
Analysis · QNTM · Life Sciences
Cash burn continues, but the balance sheet is no longer running on fumes: cash nearly doubled to $3.56M and working capital reached $5.47M, helped by $10.6M of at-the-market share sales and C$3.75M of March 2026 debentures. That funding carries a visible cost in the share count — 2.8M ATM shares plus 1.09M shares from debenture conversions in nine months — and in $2.17M of warrant liability and $684,619 of derivative liability on the balance sheet. The nine-month net loss narrowed to $17.3M from $23.3M, but $9.0M of that loss is a non-cash mark-to-market charge on those derivative and warrant liabilities, not cash leaving the business. The near-term binary is legal: the GBB Drink Lab trade-secrets trial starts November 30, 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNTM was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.4M. The 52-week trading range was $1.71 to $12.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.